HAVN LIFE SCIENCES INC. (F:5NP0) — Market Cap & Net Worth
Market Cap & Net Worth: HAVN LIFE SCIENCES INC. (5NP0)
HAVN LIFE SCIENCES INC. (F:5NP0) has a market capitalization of $172.31K (€147.39K) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #30856 globally and #2772 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HAVN LIFE SCIENCES INC.'s stock price €0.01 by its total outstanding shares 14738600 (14.74 Million).
HAVN LIFE SCIENCES INC. Market Cap History: 2020 to 2026
HAVN LIFE SCIENCES INC.'s market capitalization history from 2020 to 2026. Data shows change from $386.66 Million to $172.31K (-72.50% CAGR).
HAVN LIFE SCIENCES INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HAVN LIFE SCIENCES INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5NP0 by Market Capitalization
Companies near HAVN LIFE SCIENCES INC. in the global market cap rankings as of May 4, 2026.
Key companies related to HAVN LIFE SCIENCES INC. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
HAVN LIFE SCIENCES INC. Historical Marketcap From 2020 to 2026
Between 2020 and today, HAVN LIFE SCIENCES INC.'s market cap moved from $386.66 Million to $ 172.31K, with a yearly change of -72.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €172.31K | 0.00% |
| 2025 | €172.31K | 0.00% |
| 2024 | €172.31K | 0.00% |
| 2023 | €172.31K | -80.00% |
| 2022 | €861.55K | -98.60% |
| 2021 | €61.41 Million | -84.12% |
| 2020 | €386.66 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of HAVN LIFE SCIENCES INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $172.31K USD |
| MoneyControl | $172.31K USD |
| MarketWatch | $172.31K USD |
| marketcap.company | $172.31K USD |
| Reuters | $172.31K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HAVN LIFE SCIENCES INC.
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psil… Read more